Twist Bioscience Co. (NASDAQ:TWST) Position Lessened by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. lowered its position in Twist Bioscience Co. (NASDAQ:TWST) by 29.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,283 shares of the company’s stock after selling 5,127 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Twist Bioscience were worth $453,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. EdgeRock Capital LLC acquired a new position in Twist Bioscience in the fourth quarter worth approximately $30,000. Federated Hermes Inc. acquired a new position in shares of Twist Bioscience during the 3rd quarter worth $29,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Twist Bioscience by 96.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock valued at $30,000 after purchasing an additional 721 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Twist Bioscience by 51.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock valued at $70,000 after purchasing an additional 1,179 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in Twist Bioscience by 3,519.8% in the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after purchasing an additional 3,907 shares in the last quarter.

Twist Bioscience Price Performance

TWST stock traded up $1.80 on Thursday, reaching $43.20. 854,570 shares of the company were exchanged, compared to its average volume of 999,100. The firm has a market capitalization of $2.52 billion, a PE ratio of -12.86 and a beta of 1.64. Twist Bioscience Co. has a 12 month low of $11.81 and a 12 month high of $44.92. The stock’s fifty day moving average price is $34.18 and its 200 day moving average price is $31.59.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The company had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. During the same quarter in the previous year, the firm posted ($1.06) EPS. The business’s revenue was up 25.1% compared to the same quarter last year. As a group, research analysts expect that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on TWST shares. The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $25.00 to $45.00 in a research report on Wednesday, January 17th. Barclays boosted their target price on Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Scotiabank increased their price target on Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Finally, Evercore ISI lifted their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $42.50.

Insider Buying and Selling at Twist Bioscience

In other news, insider William Banyai sold 798 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total transaction of $29,629.74. Following the sale, the insider now directly owns 345,188 shares in the company, valued at $12,816,830.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider William Banyai sold 798 shares of the company’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $29,629.74. Following the sale, the insider now owns 345,188 shares of the company’s stock, valued at $12,816,830.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Patrick John Finn sold 2,174 shares of the business’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total value of $65,480.88. Following the completion of the sale, the chief operating officer now directly owns 176,206 shares in the company, valued at approximately $5,307,324.72. The disclosure for this sale can be found here. Insiders sold a total of 17,415 shares of company stock valued at $614,504 in the last quarter. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.